img

Follow Us

  • linkedin
  • fb
  • insta
  • youtube
slider
slider

WELCOME TO ABDUL LATIF JAMEEL HEALTH

Delivering real-world
solutions

slider

WELCOME TO ABDUL LATIF JAMEEL HEALTH

Driven by innovation
in all we do

slider

WELCOME TO ABDUL LATIF JAMEEL HEALTH

Working with
world-leading partners

slider

WELCOME TO ABDUL LATIF JAMEEL HEALTH

Investing in the
future of health-tech

slider

WELCOME TO ABDUL LATIF JAMEEL HEALTH

Accelerating access to
modern medical care

download icon

Abdul Latif Jameel Health

Brochure PDF file 1.80 MB

Loading…

News & Insights

  • INSIGHT NEWS
  • INSIGHT NEWS
  • INSIGHT NEWS
  • INSIGHT NEWS
NEWS
Abdul Latif Jameel Health and Bader Sultan & Brothers Co. announce new collaboration agreement

Abdul Latif Jameel Health and Bader Sultan & Brothers Co. announce new collaboration agreement for Butterfly iQ+ ultrasound solution in Kuwait

February 14, 2023  |  Dubai, UAE
Read More
New partnership with iSono Health

Abdul Latif Jameel Health and iSono Health join forces to bring the world’s first AI-driven portable 3D breast ultrasound scanner to potentially help hundreds of millions of women in over 30 countries across the Global South

January 30, 2023  |  Dubai, UAE & South San Francisco, USA
Read More
Abdul Latif Jameel Health and EQRx to introduce two affordable cancer treatments

Abdul Latif Jameel Health to collaborate with EQRx to introduce two novel and affordable cancer treatments at a fraction of the cost of existing approaches to 1.5 billion people across the Middle East, Turkey and Africa

November 22, 2021  |  Dubai, UAE
Read More
Abdul Latif Jameel Health and Butterfly Network enter strategic distribution partnership

Abdul Latif Jameel Health & Butterfly Network enter strategic distribution partnership to bring Butterfly iQ+ ultrasound device to 2 billion people across Middle East, North Africa, Turkey & India

November 15, 2021  |  Dubai, UAE
Read More
SEE ALL NEWS
  • INSIGHT NEWS
  • INSIGHT NEWS
  • INSIGHT NEWS
  • INSIGHT NEWS
INSIGHTS
Are we any closer to a cure for cancer?

Scientists had long been eyeing mRNA as a revolutionary weapon in the war against cancer. The avalanche of funding, resources and talent that poured into the mRNA field heralded a game-changing moment in cancer research. It promised nothing less than a new breed of mRNA treatments designed to boost the body’s immune response against unwanted cell mutation.

May 2, 2023  |  Dubai, UAE
Read More
Halting the march of metabolic syndrome

In medical lexicon ‘metabolic syndrome’ (MetS) might not exactly trip from the tongue like ‘heart disease’ or ‘cancer’. Yet, depending on where you live in the world, there could be a one-in-three chance you have the condition already. And despite its relative obscurity, be in no doubt: its impact is life threatening.

February 10, 2023  |  Dubai, UAE
Read More
Resistance is not futile

For most of human history, even the tiniest of scratches could prove fatal. Never mind pneumonia, childbirth or surgery, gardening was a potentially deadly pursuit. A graze or scratch could become infected, and there was very little you could about it apart from hoping the harmful microbes didn’t spread. It was basically your immune system versus the bacteria.

December 9, 2022  |  Dubai, UAE
Read More
Sharing the benefits of health tech innovation

A Q&A with Wellesta on its new partnership with Abdul Latif Jameel Health

November 4, 2022  |  Dubai UAE and Mumbai, India
Read More
SEE ALL NEWS
ABOUT US

Abdul Latif Jameel Health
Accelerating access adding value

We are committed to adding real, tangible value, not only to all our business partner relationships but also to the communities in which we operate.

As a solutions partner, we strongly believe in success through service – working together with stakeholders; taking a structured, systemic, focus to delivering on our promises.

With this approach, we are accelerating access to modern medical care for more people in more places and for those that need it most.

About Us

Who we are

Abdul Latif Jameel Health was founded in 2020, as our response to one of the greatest problems of today’s global society – the disparity in access to modern medical care, notably in the fast-growing markets and economies of the developing world

Backed by Abdul Latif Jameel, – one of the regions most respected diversified family businesses and investors, with a 75-year heritage, deep roots and established networks and a multi-sector presence in 30 countries across six continents – Abdul Latif Jameel Health is uniquely positioned as a trusted partner to realize the exciting opportunities ahead.

Our approach

Abdul Latif Jameel Health builds on the Jameel family’s long established philanthropy, Community Jameel, and its’ focus on innovating for a better future by seeking to solve problems at source.

This includes the co-founding of the Abdul Latif Jameel Clinic for Machine Learning in Health (Jameel Clinic) at MIT and the Abdul Latif Jameel institute for Disease & Emergency Analytics (Jameel Institute) at Imperial College London.

Abdul Latif Jameel Health takes this philosophy into the commercial environment addressing tangible real-world needs today – for a better tomorrow.

Downloads

download icon

Abdul Latif Jameel Health
Brochure

PDF file 1.80 MB

Watch Full Video
Watch Full Video
Choose Language
icon Impact

We are committed to making a meaningful impact. That’s why we are:

  • Focused on countries with unmet medical need and growing healthcare demands
  • Focused on delivering a differentiated high-quality service to our partners
icon Quality

We believe quality is an inviolable essential that must be designed-in. That’s why we are:

  • Investing in mutually beneficial and sustainable partnerships
  • Driven by the pursuit of excellence
  • Leveraging more than 75 years of proven international delivery
  • Investing in breakthrough and innovative technologies
icon Infrastructure

We are conceiving our infrastructural solutions around innovation to develop capabilities that address all segments of healthcare industry, eventually including:

  • R&D – manufacturing
  • Medical device & diagnostics
  • Distribution & retail solutions
  • Healthcare services

WHAT WE DO

Harnessing key trends as drivers of success

We are continually exploring emerging trends and innovation in technology, therapeutics and business models to accelerate access to modern medical care in growing markets and developing economies.

Technology adoption
Technology adoption

The rapid innovation cycle in global health technology , including AI, therapeutics, medical devices, regenerative medicine and more, presents significant opportunities.

This is impacting drug and device filing, registration and market authorization as well as licensing arrangements.

We seek to both invest in emerging ideas and connect businesses to new growth opportunities particularly in rapidly developing markets.

Global health security
Global health security

Increasing resilience in our society’s healthcare systems and processes to increase public and private health security has become a pressing need both nationally and internationally across borders.

With our international networks and relationships, we are uniquely positioned to be a key player in this emerging environment helping our partners to deliver and realizing our overarching goal of expanding access to modern health care.

Maturing regulatory environment
Maturing regulatory environment

The increasing momentum in regulation is creating clarity in, and thereby helping to enable access to, new markets as governments in developing economies seek to fast track wider and more comprehensive access to healthcare for their populations

This includes more rapid approval processes for innovative medicines; technology assessment and approval, and more structured clinical guidelines. We are able to navigate these new opportunities, benefiting our partners and the community.

Expansion of healthcare coverage
Expansion of healthcare coverage

There is a growing commitment of governments around the globe to drive universal health coverage policies.

In parallel, growing demand for health insurance coverage continues to demand innovative funding models.

In turn this requires the expansion of the role of Public-Private Partnership models in healthcare to enable access, where we are ready and able to play an enabling role.

Patient centricity
Patient centricity

Increasing patient centricity worldwide continues to drive the importance of patient education and support programs.

We are ready to play our role in enabling individuals to take an active interest in their own health management.

Localization - local partnerships
Localization – local partnerships

Tailoring health solutions to local markets is a key pre-requisite for success. Government endorsement and incentives to promote local manufacturing are driving momentum and a rising investment in local manufacturing.

We are continually fostering our network of local partnerships, globally, to develop tangible and sustainable local solutions.

ceo
We’re partnering with those who share our vision for life, and lives, by accelerating accessibility to health care in areas of the world with unmet needs and that present a commercial opportunity – where we can add tangible value to both the community and for our partners.

Akram Bouchenaki
Chief Executive Officer
Abdul Latif Jameel Health

OUR SOLUTIONS

An integrated solutions portfolio

Underpinned by innovation in all we do, we are evolving our capabilities to cover all segments of the health care industry. We are developing expertise across medical devices, pharmaceuticals and diagnostics distribution, and will also provide a comprehensive range of associated healthcare business partner services.

We will offer a single relationship solution delivering tailored services specifically designed to accommodate our partners’ needs – a fully integrated proposition from registration to distribution and promotion and regulatory services.

We remain focused on accelerating access to modern medical care, while addressing unmet medical needs in developing countries and growth markets around the world.

We’re constantly exploring new opportunities and long-term investments to provide the best solutions and we evaluate ways to partner with innovators, global market leaders, investors, healthcare providers and government entities that share our vision.

solution icons
Registration and
regulatory solutions

New market entry requires understanding and management of complex local regulations and practices. We offer a range of solutions including.

  • Drugs and device filing and registration solutions
  • Marketing and promotional authorization solutions
  • Regulatory approval and certification solutions
  • Licensing solutions
solution icons
Logistics and
distribution solutions

We offer a full range of logistics and distribution solutions across the markets in which we operate and a network of trusted partners beyond.

  • Wholesale export depository solutions
  • Distribution of products and samples
  • Product localization through secondary packing solutions
solution icons
Promotion, Marketing

Raising awareness and trial of new technologies and therapies demands appropriate dialogue and communication on-ground. Our local knowledge can help you achieve this.

  • Design and implement go to market strategies
  • Deploy sales and representation solutions
  • Manage tender opportunities
  • Education of the medical community and patients
solution icons
Pharmacovigilance
solutions

In-market pharmacovigilance is critical to export success and approval. We can help you navigate the local requirements.

  • Solutions to assess and monitor pharmaceutical effects
  • Integrated workflow solutions with both regulatory and partner surveillance systems

FEATURED MARKET

Africa

With over 60 countries and more than 1.5 billion people; the African continent represents both a pressing need, and a clear opportunity to accelerate access to modern medical care.

Africa offers a compelling opportunity with an unparalleled addressable market size and associated growth prospects.

Macro socio-economic trends favor growth. Not least of which is a maturing regulatory environment, clear government ambition and increasing stability and a young and savvy population wanting to better manage their health.

Half of all Africans are under 19 years of age, and with increasing urbanization, education, and commerce, incomes and demand for healthcare is rising quickly.

From the megacities to rural communities, access to modern medical care is an issue that must be addressed.

At Abdul Latif Jameel Health, we are exploring and pioneering relationships to make this a reality.

Selected Partners

EQRx

EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices. Leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before.

In 2021, Abdul Latif Jameel Health announced a partnership to become EQRx’s regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.

Butterfly Network

Butterfly Network created the world’s only handheld, single-probe whole-body ultrasound system using semiconductor technology, the Butterfly iQ. Its mission is to democratize medical imaging and contribute to the aspiration of global health equity by making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected—including for the 4.7 billion people around the world lacking access to ultrasound.

In 2021, Abdul Latif Jameel Health entered a strategic distribution partnership to bring Butterfly iQ+ ultrasound device to a potential 2 billion people across the Middle East, North Africa, Turkey & India.

Cyberdyne

Cyberdyne Inc. of Japan are world leading innovative pioneers of AI-robotic solutions including the Hybrid Assisted Limb (HAL)®

Abdul Latif Jameel was the first to introduce HAL®and ‘Cybernics Therapy’ into Saudi Arabia at the Abdul Latif Jameel Rehabilitation Hospital, Jeddah, teaching spinal injury patients to regain use of their limbs. The relationship has since expanded to include the GCC with the Hospital as a regional training center.

Cellspect

Japanese immunology, biochemistry and healthtech pioneer Cellspect is developing breakthrough highly portable point-of-care-testing (POCT) devices that can address the needs of dispersed populations.

In 2019, Abdul Latif Jameel began a collaboration with Cellspect to bring these low-cost POCT devices to developing markets.

JOMDD

Japanese innovative investment platform, JOMDD, specializes in investing and commercializing transformative new technologies in medical device development.

In early 2020, Abdul Latif Jameel and JOMDD announced their investment/incubator partnership to bring innovative Japanese medical device technology to developing markets

AV Neo

AVNeo (Aortic Valve Neocuspidization) is a standardized revolutionary procedural technique used to reconstruct the aortic heart valve using the patient’s own pericardial tissue.

Partnering with JOMDD and the Saudi Arabian Ministry of Health, Abdul Latif Jameel Health is introducing this pioneering life saving procedure into Saudi Arabia. Latest data showed the 10-year survival rate was 85.9% for AVNeo compared to less than 80% for alternative procedures.

down prev-arrow
down next-arrow

Investing in health care inclusion for all

At Abdul Latif Jameel Health, we provide integrated distribution and in-market services solutions for our partners, opening new opportunities across the developing world to accelerate access to modern health care for those that need it most – but we’re doing so much more through our targeted investments.

Abdul Latif Jameel Health reflects the Jameel family’s long-established commitment to innovating for a better future through Community Jameel, an international organization supporting science and technology-led solutions to global challenges. Community Jameel and MIT co-founded the Abdul Latif Jameel Clinic for Machine Learning in Health (Jameel Clinic) in September 2018 – which has rapidly become the very epicenter of AI and healthcare at MIT – and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (Jameel Institute) co-founded with Imperial College London, in October 2019, using novel data analytics to reduce global risk of preventable disease most recently including the 2020 COVID-19 pandemic, and strengthening health systems in the most fragile settings.

Abdul Latif Jameel Health takes this commitment into the commercial environment addressing tangible real-world needs today, for a better tomorrow.

It is focused on health care inclusion in the global south, accelerating access to modern medical care for those who need it most by opening up/growing new markets for distribution of existing solutions and investing in the future of MediTech.

Abdul Latif Jameel actively invests in innovative, early-stage and breakthrough ventures and technology, aiming to positively shape the future of core industries driving the global economy through its’ investments that span medical and healthcare industries, from pharmaceuticals and vaccines to cutting-edge medical technology, along with emergent technologies across FinTech, InsurTech, electric vehicles and future mobility solutions.

Evelo Biosciences Logo

Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, with systemic therapeutic effects.

This plays a central role in governing the immune, metabolic, and neurological systems.  Evelo’s therapies have the potential to improve the lives of people with inflammatory diseases – including COVID-19 – and cancer.

Cellarity Logo

Founded in 2017, Cellarity is a first-of-its-kind therapeutics company discovering and developing medicines by studying and altering cell behaviors.

Cellarity developed a powerful, generalizable platform harnessing single-cell technologies and machine learning to unveil the network state of a given cell, defining the cell’s behavior.  Cellarity’s platform digitizes and quantifies cellular behaviors, unravels the network dynamics that govern those behaviors, and generates medicines that can direct them.

Laronde-logo-for-ALJ-Health

Laronde was founded in 2017, and is pathfinding a platform that offers a completely novel way of modulating human biology. Endless RNA™ (eRNA), is a uniquely engineered RNA that can be programmed to express diverse therapeutic proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery.

down prev-arrow
down next-arrow

Contact Us

Abdul Latif Jameel Health

W www.aljhealth.com

Follow Us

  • Linkedin
  • Facebook
  • instagram
  • Youtube
col transparent
col transparent
alj.comcommunityjameel.org

Download our News and Insights App

Google Play Store Logo
Apple Store Logo

© 2023 Meddist Company Limited. Permission to use this site is granted strictly subject to the Terms of Use.

The Abdul Latif Jameel name and the Abdul Latif Jameel logotype and pentagon-shaped graphics are trademarks or registered trademarks of Abdul Latif Jameel IPR Company Limited.